EP0382790A4 - Compositions and methods for alleviating stress, anxiety and seizure activity - Google Patents

Compositions and methods for alleviating stress, anxiety and seizure activity

Info

Publication number
EP0382790A4
EP0382790A4 EP19890900688 EP89900688A EP0382790A4 EP 0382790 A4 EP0382790 A4 EP 0382790A4 EP 19890900688 EP19890900688 EP 19890900688 EP 89900688 A EP89900688 A EP 89900688A EP 0382790 A4 EP0382790 A4 EP 0382790A4
Authority
EP
European Patent Office
Prior art keywords
anxiety
compositions
methods
seizure activity
alleviating stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890900688
Other languages
English (en)
Other versions
EP0382790A1 (en
Inventor
Kelvin W. Gee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0382790A1 publication Critical patent/EP0382790A1/en
Publication of EP0382790A4 publication Critical patent/EP0382790A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19890900688 1987-08-25 1988-08-24 Compositions and methods for alleviating stress, anxiety and seizure activity Withdrawn EP0382790A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8936287A 1987-08-25 1987-08-25
US89362 1987-08-25

Publications (2)

Publication Number Publication Date
EP0382790A1 EP0382790A1 (en) 1990-08-22
EP0382790A4 true EP0382790A4 (en) 1991-03-27

Family

ID=22217242

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890900688 Withdrawn EP0382790A4 (en) 1987-08-25 1988-08-24 Compositions and methods for alleviating stress, anxiety and seizure activity

Country Status (5)

Country Link
EP (1) EP0382790A4 (da)
JP (1) JPH03500049A (da)
AU (1) AU609927B2 (da)
DK (1) DK48790A (da)
WO (1) WO1989002272A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
EP2030622B1 (en) 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
FI2753632T3 (fi) * 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
CA3152410A1 (en) * 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
KR102917075B1 (ko) * 2018-02-11 2026-01-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 스테로이드 유도체 조절제, 그의 제조 방법 및 그의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB804522A (en) * 1954-10-21 1958-11-19 Pfizer & Co C Steroids and the preparation thereof
FR1549153A (da) * 1962-06-15 1968-12-13
US3558673A (en) * 1966-10-29 1971-01-26 Ormonoterapia Richter Spa 10beta-amino-19-nor-pregnanes and method for the preparation thereof
FR2281123A1 (fr) * 1974-08-05 1976-03-05 Schering Ag Oxo-20 pregnanes et medicaments qui en contiennent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2414514A1 (fr) * 1978-01-11 1979-08-10 Roussel Uclaf Nouveaux derives steroides 17aaryle ou aheteroaryle, leur procede de preparation et leur application comme medicament
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4605649A (en) * 1983-02-22 1986-08-12 Liehr Joachim G Method of treatment of estrogen deficiency disease
FI83087C (fi) * 1984-05-16 1991-05-27 Schering Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara estriol-3,17-diestrar.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB804522A (en) * 1954-10-21 1958-11-19 Pfizer & Co C Steroids and the preparation thereof
FR1549153A (da) * 1962-06-15 1968-12-13
US3558673A (en) * 1966-10-29 1971-01-26 Ormonoterapia Richter Spa 10beta-amino-19-nor-pregnanes and method for the preparation thereof
FR2281123A1 (fr) * 1974-08-05 1976-03-05 Schering Ag Oxo-20 pregnanes et medicaments qui en contiennent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8902272A1 *

Also Published As

Publication number Publication date
JPH03500049A (ja) 1991-01-10
DK48790D0 (da) 1990-02-23
WO1989002272A1 (en) 1989-03-23
AU609927B2 (en) 1991-05-09
AU2828389A (en) 1989-04-17
EP0382790A1 (en) 1990-08-22
DK48790A (da) 1990-04-25

Similar Documents

Publication Publication Date Title
EP0311983A3 (en) Method for the preparation of titanium-silicalites
GB8610297D0 (en) Turbomachinery
GB8712844D0 (en) Adjustable-width seating
EP0234223A3 (en) Method for the preparation of aromatic block copolyethers
DE3561864D1 (en) Solid silicone defoaming agent and method for its production
GR871701B (en) Method for preparing 5,6 - dihydrixyindol, and its 3 - alkylated derivative and intermediates
EP0183436A3 (en) Methods, compositions and uses thereof for reduction of stress
AU8170091A (en) Compositions and methods for alleviating stress, anxiety and seizure activity
IL76243A0 (en) Process and intermediates for the preparation of aromatic-1,4-oxazepinones and-thiones
AR244658A1 (es) Metodo mejorado para la preparacion de anilinofumaratos.
EP0297447A3 (en) Method for the preparation of 2-cyclopentenones
ZA862695B (en) Composition,method for preparing and use thereof
EP0161548A3 (en) Process for the preparation of riboflavin, and intermediates for this process
BG47569A1 (en) 1- thiocarbamoylmethylpyrolidene- 2- tion and method for its preparation
BG43438A1 (en) 2- phenyl- 1h- indene- 1, 3 (2h)- dions and method for their preparation
CS967687A1 (en) Method of 2,6-dialkyl-n-/1 -methoxy-2-propylidene/aniline preparation
BG42754A1 (en) Thiphosphatic derivative of ethylaminopropionamid, method for preparation and its use
GB8616195D0 (en) Furniture construction method
BG48273A1 (en) Polymerisationable oligoimide and method for its preparation
BG40061A1 (en) (+)- 4- phenyl- 2- methyl- 8- amino- 1, 2, 3, 4- tetrahydroisoquinoline and method for its preparation
IL73371A0 (en) Compositions and method for the modification of insulin activity
RO101419B1 (en) Diphenylmethane methyl - substitute preparation method
CS967587A1 (en) Method of 2,6-dialkyl-n-/l-methoxy-2-propyl-aniline preparation
CS490187A1 (en) Method of 2,5-dibutoxy-4-morpholine-benzendiazononium preparation
CS803287A1 (en) Method of 0,0-dimethyl-s-phthalimidomethyldithiophosphate preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI SE

17Q First examination report despatched

Effective date: 19921022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941116